HOV-12020 (Palm tocotrienols complex) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 124 | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy | 1 |
124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
Clinical trials : 12 / Drugs : 14 - (DrugBank : 5) / Drug target genes : 3 - Drug target pathways : 11
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04658823 (ClinicalTrials.gov) | December 21, 2020 | 29/11/2020 | Efficacy and Safety of Tocotrienols in CADASIL | A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) | Cadasil | Drug: HOV-12020 (Palm tocotrienols complex);Drug: Placebo | Hovid Berhad | NULL | Active, not recruiting | 45 Years | 75 Years | All | 50 | Phase 2 | France |